Current therapies for the hepatitis B virus (HBV), a major cause of severe liver disease, suppress viral replication but replication rebounds if therapy is withdrawn. It is widely accepted that immune activation is needed to control replication off-therapy. To specifically activate T cells crossreactive between the hepatitis B core and e antigens (HBcAg/HBeAg) in chronically infected patients, we developed a therapeutic vaccine candidate. The vaccine encompass codon-optimized HBcAg and IL-12 expressing plasmids delivered using targeted highpressure injection combined with in vivo electroporation. One dose of the vaccine primed a B-cell-independent polyfunctional T-cell response, in wild-type, and in HBeAg-transgenic mice with an impaired ability to respond to HBc/eAg. The response peaked at 2 weeks and contracted at week 6 after vaccination. Coadministration of IL-12 improved antibody levels, and T-cell expansion and functionality. The vaccine primed T cells that, 2 weeks after a single dose, cleared hepatocytes transiently expressing HBcAg in vaccinated wild-type and HBeAg-transgenic mice. However, 4 weeks later, these functional responses were lost. Booster doses after 8-12 weeks effectively restored function and expansion of the rapidly contracting T cells. Thus, this vaccine strategy primes functional HBcAg-specific T cells in a host with dysfunctional response to HBV.
INTRODUCTION
The hepatitis B virus (HBV) causes chronic infections that increase the risk for severe liver disease and cancer. Existing nucleoside-based therapies that effectively block the reverse transcriptase (RT) function of HBV decrease the viral load. However, when treatment is stopped, viral replication resume as these drugs are not effective in generating sustained off-therapy responses. 1 It has now been shown that a long-term (>5 years) therapy with these drugs can reduce the risk of cancer. 2 However, with a longer duration of therapy, the risk for side effects and appearance of drug resistant viral variants increase. 3 Several studies have highlighted the importance of the host immune response in controlling acute and chronic HBV infections. [4] [5] [6] In particular, the spontaneous or interferon-treatment induced control of infection is tightly associated with an increase in the T-cell response to both the hepatitis B core antigen (HBcAg) and hepatitis B e antigen (HBeAg), [7] [8] [9] since these two antigens are crossreactive on the T-cell level. Thus, it is likely that T-cell activation is required for a sustained off-therapy response. Early reports of using lamivudine indicated that T-cell responses might be partially restored during lamivudine therapy. 10, 11 Although immune responses are likely to recover as viral replication is suppressed, this recovery is not effective enough to achieve off-therapy responses. One explanation may be that the RT inhibitors act during virion maturation by preventing the encapsidated RNA pregenome to be converted to the partially double-stranded DNA. These drugs cannot suppress the production of transcripts and viral antigens from the covalently closed circular (ccc) DNA. Hence, RT inhibitors do not block antigen production in already infected cells, but can reduce the spread of the infection. This is evidenced by a drop in the serum levels of HBV DNA, but not in hepatitis B surface antigen (HBsAg), and a reduced HBcAgproduction in the liver. 12, 13 However, this does not result in sustained off-therapy responses.
To (re)activate the host immune response, we, and others, have developed therapeutic vaccines for the treatment of chronic infections caused by the HBV and the hepatitis C virus (HCV). [14] [15] [16] [17] [18] Therapeutic vaccination alone can transiently activate T-cell responses and decrease viral load in chronically infected humans, albeit to date not sufficiently to sustainably control or clear viral replication. 16, 17 Thus, improved vaccines are needed that can activate T cells even in a chronically infected host with a most likely dysfunctional T-cell response to the infecting virus. 19 The goal of a therapeutic vaccine is to induce broad HBV-specific immune responses that help to control the HBV infection. 20, 21 This goal is a consequence of the observations that broad, and polyfunctional T-cell responses are important in controlling chronic viral infections. 22, 23 We have previously shown that the immunogenicity of a DNA-based HBcAg vaccine was effectively enhanced through codon optimization (co) and delivery by in vivo electroporation (EP), or electrotransfer (ET). 24 We have also shown that addition of HBcAg sequences improves the immunogenicity of a HCV nonstructural (NS) 3/4A-based vaccine in a host with impaired immune responses to HCV. 25 We here evaluate several approaches to improve the immunogenicity of a therapeutic vaccine candidate (+SD) with a cutoff set at 50 SFCs/10 6 splenocytes. Statistical differences have been evaluated between groups of mice immunized with or without IL-12 as *P < 0.05, ***P < 0.001 using area under the curve (AUC) and analysis of variance (ANOVA). In (e), the expansion of HBcAg-specific CD8 + T cells was determined using direct ex vivo pentamer staining. MGLKFRQL epitope-specific CD8 + T cells are shown as the percentage of HBcAg-pentamer positive CD8 + T cells where each filled black circle represent an individual mouse. The black horizontal line indicates the mean of the group. The statistical difference (*P < 0.05) was determined using Mann-Whitney U-test. (f) Shows the mean (+SD) endpoint dilution (three times background value (negative sera)) of anti-HBc IgG antibody titers 2 weeks after last immunization in each group of mice. NS, not significant, indicates no statistical difference, and *P < 0.05 (Mann-Whitney U-test). (refs. 26-28) . This results in a dysfunctional Th-2-skewed T-cell response toward both HBcAg and HBeAg that can be activated by various immunizations. [26] [27] [28] This is therefore a suitable model to evaluate vaccine improvements and the effects of including the antiviral cytokine interleukin (IL)-12, important for viral clearance of HBV and plays a role in shaping the T-cell repertoire. 29, 30 
RESULTS

Improving DNA vaccine delivery
As a key step in improving immunogenicity of genetic material in vivo, we developed a new technology termed in vivo intracellular injection (IVIN; Figure 1 ). The IVIN technology is based on a device with multiple needles where several holes (between 72-144 holes depending on the design) have been laser cut along the needle shafts (Figure 1a) . The idea is to isolate a specific volume of tissue and then overload it with a vaccine-containing solution, similar to a hydrodynamic injection. 31 In the overloaded tissue, the plasmid DNA is more effectively taken up by muscle cells, resulting in an increased expression of the vaccine antigen ( Figure  1b) . In mice, the injection is a forced (19 newton, N) injection of 30 μl of plasmid DNA controlled by a spring-loaded device, to obtain a controlled pressure and a high reproducibility (Ahlen et al., unpublished data). To evaluate the IVIN technology, we first used the HCV NS3/4A-based DNA vaccine.
17 NS3 proteinexpression was determined in paraffin embedded sections from mouse tibialis cranialis muscle tissue from mice immunized using regular intramuscular injection (IM) or the IVIN device alone or in combination with in vivo EP (Figure 1b) . This suggested that the IVIN technology by itself improved transfection efficiency and, importantly, caused local inflammation, as compared to a standard needle injection (Figure 1b) . The combination of IVIN followed by in vivo EP further improved NS3-protein expression (Figure 1b) . We therefore used the IVIN technology combined with in vivo EP in the current study.
Optimizing the priming milieu
Previous studies where HBcAg has been endogenously expressed through genetic vaccination have shown priming of both humoral and cellular immune responses in mice. 24, 32, 33 We could show that the ability of endogenous HBcAg to induce cytotoxic T lymphocytes (CTLs) was improved by increasing plasmid uptake and expression levels through in vivo EP. 24 To further improve immunogenicity, we here used the IVIN technology combined with in vivo EP and evaluated the addition of a plasmid expressing IL-12. The inclusion of IL-12 increased immunogenicity by more than 100% in both wildtype and HBeAg-Tg mice as determined by the number of IFNγ-producing cells by enzyme-linked immunospot (ELISpot) ( Figure  1c ). Both CD4 + Th (HBcAg Th) and CD8 + CTL (HBcAg CTL) responses were significantly improved in the wild-type mice whereas mainly the CTL responses were improved in the HBeAg-Tg mice. There was a significant increase in the number of IL-2-producing cells in wild-type mice, whereas the overall IL-2 response was low after a single vaccination in HBeAg-Tg mice (Figure 1d and data not shown). Furthermore, a significantly higher frequency of HBcAgspecific CD8 + T cells, as detected by direct ex vivo pentamer staining, was primed using IL-12 in comparison to the HBcAg vaccine alone (Figure 1e , P < 0.05, Mann-Whitney U-test). Unexpectedly, also HBcAg-specific IgG antibody levels were improved by IL-12 in both wild-type and HBeAg-Tg mice at 2 weeks after a single immunization, albeit a statistical difference was only observed in wild-type mice (Figure 1f , P < 0.05 and NS, Mann-Whitney U-test).
IL-12 improves HBcAg-specific T-cell polyfunctionality
To better characterize the immunogenicity of the HBcAg-based DNA vaccine, the polyfunctionality of the CD8 + T cells was determined at 2 weeks after a single immunization. This showed that the inclusion of IL-12 increased the proportion of trifunctional HBcAgspecific T cells expressing tumor necrosis factor-α (TNF-α), IFN-γ, and CD107a (Figure 1g ).
Vaccine-primed T cells eliminate HBcAg-expressing hepatocytes in HBeAg-transgenic mice
We have previously shown that HBcAg vaccine-primed T cells eliminate HBcAg-expressing hepatocytes in transiently transgenic wild-type mice. 24 We here tested whether vaccineinduced T cells could eliminate hepatocytes expressing HBcAg also in HBeAg-transgenic mice, which have an impaired T-cell response to both HBcAg and HBeAg. The comparison of nonimmunized wild-type (245 ± 61) or HBeAg-Tg (278 ± 54), did not reveal any differences. However, HBeAg-Tg mice vaccinated with 5 μg HBcAg and 5 μg IL-12 2 weeks before the hydrodynamic challenge had completely cleared HBcAg-expressing cells within 72 hours from the hydrodynamic injection (Figure 2a,c) . Naive and vaccinated HBeAg-Tg mice were challenged with a mixture of HBcAg-and luciferase-expressing plasmid, and at 24-72 hours postchallenge, there was significantly less HBcAg/ luciferase detected in the vaccinated HBeAg-Tg mice ( Figure  2b , P < 0.05, area under the curve (AUC) and analysis of variance (ANOVA). Thus, the vaccine-primed, HBcAg-specific T cells were functional in vivo.
Longevity of primed T cells after a single immunization
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Restoration of functional T-cell and B-cell responses
Since the immune response after a single immunization was short-lived, we determined whether a booster immunization could restore or improve the longevity of these responses. To determine the best timing for the booster dose, we immunized groups of wild-type and HBeAg-Tg mice twice with 4, 8, or 12 weeks between immunizations. The peak number of IFN-γ SFCs after peptide stimulation was consistently observed 2 weeks after a single immunization in both wild-type and HBeAg-Tg mice (IVIN-EP) . The groups of mice that were immunized twice had 4, 8, or 12 weeks between immunizations. Two weeks after last immunization, mice were bled and serum was tested for anti-HBc IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3). All data are given as individual end point titers (black filled circles) with each groups mean titer indicated (line). (Figure 4b) . The induction of HBcAg-specific IgG antibodies was significantly improved after two immunizations as compared to one vaccination in both wild-type and HBeAg-Tg mice (Figure   4c , P < 0.05, Mann-Whitney U-test). These data suggest that immune responses against HBcAg can be boosted using repeated immunization strategies.
Booster vaccinations alter the Th1/Th2-balance as determined by IgG subclass responses
To further evaluate the effect of the booster response, we characterized anti-HBc IgG subclass distribution in the vaccinated mice ( Figure 5 ). All IgG subclasses were detected, with a predominant IgG2b response in both wild-type and HBeAg-Tg mice, an intrinsic property of HBcAg. 34, 35 The most obvious effect was seen 2 weeks after a booster immunization as IgG2a increased 1 Figure 6 Priming of T-cell responses is partly independent of B cells. Groups of five C57BL/6J and B -/-mice were immunized twice with 5 μg coHBcAg plasmid DNA alone or in combination with 5 μg IL-12 plasmid DNA by intramuscular immunization using regular needle injection in combination with in vivo EP. Two weeks after the last immunization, the mice were sacrificed and splenocytes harvested for determination of T-cell responses. The number of IFN-γ spot forming cells (SFCs) was determined by enzyme-linked immunospot (ELISpot) assay in the immunized C57BL/6J and B -/-mice and in C57BL/6J nonimmunized mice as control (a). The ELISpot was determined after in vitro stimulation of splenocytes with peptides and recombinant proteins as indicated. Results are given as the mean SFCs/10 6 (+SD) splenocytes with a cutoff set at 50 SFCs/10 6 splenocytes. Statistical differences have been evaluated between the two immunized groups of mice as ***P < 0.001 using area under the curve (AUC) and analysis of variance (ANOVA). In (b), the expansion of HBcAg-specific CD8 + T cells was determined using direct ex vivo pentamer staining. MGLKFRQL epitope-specific log in both wild-type and HBeAg-Tg mice, suggesting a Th1-like response. A booster dose at 12 weeks induced a profound Th-1 skewing of the response in wild-type mice with the disappearance of IgG1 and an almost 2-log drop in IgG3.
The situation was slightly different in the HBeAg-Tg mice, known to be Th2-like in their response to HBc/eAg. 28 In these mice, all HBcAg-specific IgG subclasses increase after the booster dose, with the exception of IgG3 (Figure 5) . Again, IgG2b was the dominating IgG subclass.
Role of B cells in the priming of HBcAg-specific T cells B cells have been proposed as the primary antigen presenting cell (APC) for exogenous/extracellular HBcAg, which may or may not be the case for endogenous/intracellular HBcAg. 32 With this in mind, it is easy to envision that, at the time of a booster dose, the high levels of anti-HBc should minimize the role of B cells as APCs. To further test whether B cells play a role in T-cell priming following DNA-based vaccination with HBcAg, we determined the priming and expansion of HBcAg-specific T cells in wild-type and B-cell-deficient (B -/-) mice primed and then boosted 4 weeks later. There was no difference in HBcAg-specific CTL production of IFN-γ or the number of HBcAg-specific CD8 + T cells between the wild-type and the B -/-mice (Figure 6a ,b, P = NS (P = 0.4206, Mann-Whitney U-test)). However, the responses to the Th peptide, and peptide pools containing the same Th epitope (peptide pools aa 1-180 and aa 101-180), were significantly higher in the C57BL/6J mice as compared to the B -/-mice (Figure 6a , P < 0.001, AUC-ANOVA). This suggests that the priming and expansion of HBcAg-specific T helper cells, but not CTLs, is influenced by B cells and/or the presence of pre-existing anti-HBc after a DNAbased immunization with HBcAg.
DISCUSSION
There is little doubt that some sort of immune therapy that can adjuvant the current direct acting antivirals is needed for chronic HBV infections. Several studies have investigated HBcAg as a potential genetic-or protein-based vaccine. 32, 36, 37 A key feature needed in an HBcAg-specific therapeutic vaccine for chronic HBV is the ability to induce strong and durable T-cell responses. To optimize the immunogenicity of DNA vaccines, several approaches have been evaluated. We have shown that codon optimization of the HBcAg-based DNA vaccine combined with delivery by in vivo EP greatly improved immunogenicity of a single DNA dose. 24 As immunogenicity is pivotal for the success of a DNA vaccine, we wanted to improve on the vaccine further in a mouse model with dysfunctional T-cell responses to HBcAg and HBeAg. These types of models better resemble the situation in humans with chronic HBV infection. We here used the HBeAg-Tg mice, which have a dysfunctional T-cell response to HBcAg and HBeAg. 27 However, they are not completely tolerant and display low-avidity response to an H-2 brestricted Th epitope (129-140) reflected in a Th2-skewing of the response. 27, 28 As we clearly show in this paper, the priming of HBc/eAgspecific CTL responses is also impaired in these HBeAg-Tg mice, revealing a dysfunction also in CD8 + T-cell repertoire. Hence, this is a useful model to study vaccine-induced immune responses. To improve the vaccine, we here optimize the priming milieu at the injection site by coadministration of cytokines. IL-12 is important for an effective induction and maturation of vaccine-induced CTLs. 30, 38, 39 We found that the inclusion of an IL-12 expressing plasmid promoted the priming of HBcAg-specific T-cell responses, evidenced by a higher level of IFN-γ production and a greater number of HBV-specific CD8 + T cells. As the quality of HBV-specific T cells seems important for the outcome of the disease, 20 we also investigated the polyfunctionality of the vaccine primed T cells. Inclusion of IL-12 increased the proportion of trifunctional (IFN-γ + , TNF-α + , and CD107a + ) CD8 + T cells in both wild-type and HBeAg-Tg mice. The cells were indeed functional, since vaccine-primed T cells eradicated HBcAg-expressing liver cells in HBeAg-Tg mice. This is important since the HBeAg-Tg mice are prone to mount a Th2-skewed immune response that counteracts the priming of antiviral Th1-responses. 28 Thus, we can prime intrahepatic functional T cells in the HBeAg-Tg mouse model that better mimics the defective T-cell responses normally seen in individuals with chronic HBV.
In vivo EP is an effective way to improve uptake and expression of vaccine antigens resulting in improved T-cell priming. 24, 40, 41 To further improve delivery and uptake of DNA vaccines, we used the new IVIN technology that overloads a targeted volume of tissue with genetic material. By combining the IVIN technology with in vivo EP, we improved vaccine expression and specific immune responses (current paper and Ahlén et al., unpublished data). Thus, this is certainly a promising combination for DNA vaccine delivery.
As expected, we noted that the primed HBcAg-specific responses contracted following a single dose, and therefore, we examined the best spacing between immunizations. The vaccineinduced immune response after a single immunization contracted between 2 and 6 weeks from immunization, as evidenced by both cytokine production and in vivo functionality. A booster dose immunization given after 4, 8, or 12 weeks effectively restored the immune response. However, the same levels of T-cell activation as seen 2 weeks after the first immunization were not achieved. Several other studies have shown that heterologous prime-boost vaccination strategies are effective in boosting HBV-specific immune responses. 36, 42, 43 However, these vaccine strategies are more complex since they depend on several different vaccine antigens and delivery technologies. A homologous vaccine approach, such as described herein, is easier to move to clinical trials and more eligible for global distribution.
We used the anti-HBc IgG subclass distribution as an additional indicator of the primed Th-phenotype. We found that the most profound Th1-skewing was seen when the booster dose was given at week 12, evidenced by the loss of the Th2-driven IgG1 subclass in wild-type mice. In the HBeAg-Tg mice, there was an increase in all IgG subclasses, except for IgG3. Thus, despite a booster dose including the IL-12 plasmid, no major changes in the IgG subclass profile was seen in the Tg mice with a dysfunctional T-cell response to HBc/eAg. Since B cells have been shown to play a pivotal role in the priming of CD4 + T cells, we asked whether they also play a role in the priming of HBcAg-specific CTLs, or if this can be contributed to other APCs such as dendritic cells or macrophages. 44 Two DNA-based vaccinations of wild-type and B-cell-deficient mice confirmed that B cells were pivotal for HBcAg-specific Th-cell activation, but had no or a limited effect in CTL priming. Overall, this suggests that B cells are important in mounting a complete and broad HBcAg-specific response, and that pre-existing antiHBc most likely has no adverse effects on T-cell priming.
In conclusion, we have shown that repeated vaccinations with a combination of a codon-optimized HBcAg gene with an IL-12 expressing-plasmid using a targeted delivery effectively primes a T-cell response that is functional in the liver of a host with a dysfunctional T-cell response to HBc/eAg. These observations are useful for the development of a potent therapeutic vaccine for chronic hepatitis B. 26, 27 and express the HBeAg subtype ayw under the control of the metallothionein promoter, inducing a T-cell dysfunction to HBc/eAg. 27, 34 The animals were either purchased (Charles River Laboratories, Sulzfeld, Germany) or bred in-house. The animals were caged at 5-10 mice per cage and fed with a commercial diet (RM3 (p) PL IRR diet; Special Diet Service) with free access to food and water. All animals were 6-24 weeks of age at the start of the experiment. All experimental protocols involving animals were approved by the Ethical Committee for Animal Research at Karolinska Institutet.
MATERIALS AND METHODS
Animals
Plasmid DNA. The codon-optimized (co) HBcAg-pVAX1 plasmid (GenBank accession number DI244925.1 (http://www.ncbi.nlm.nih. gov/genbank)) has been described previously. 32 Mouse IL-12 (pORFmIL-12) was purchased from InvivoGen (San Diego). The FLuc2-gene (Promega, Madison, WI) cloned into pVAX1 has been described previously. 31 Plasmids were grown in competent TOP10 Escherichia coli (Life Technologies, Carlsbad, CA) and purified using Qiagen EndoFree Plasmid purification Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). Plasmid DNA concentration was determined spectrophotometrically and the purified DNA was dissolved in sterile phosphatebuffered saline at concentrations of 2 mg/ml. Restriction enzyme digest were performed to ensure that the plasmid contained the gene of interest with the correct size. All DNA plasmids were sequenced to ensure correct nucleotide sequence (Eurofins MWG Operon, Ebersberg, Germany).
Peptides and antigens.
A total of eighteen 20-mer peptides (each having 10 amino acid (aa) overlap) covering the HBcAg aa 1-180, derived from the full-length HBcAg protein were purchased from Sigma Aldrich (St Louis, MO). To be able to study both CD4 + and CD8 + T-cell responses in detail, we use two previously identified HBcAg H-2 b restricted epitopes, the HBcAg-Th peptide (H-2IA b aa sequence: PPAYRPPNAPIL (HBcAg aa 129-140)), and the HBcAg-CTL peptide (H-2K b aa sequence: MGLKFRQL (HBcAg aa 93-100)). The following non-HBV control peptides were used; SIINFEKL (OVA 257-264, CTL-epitope) and ISQAVHAAHAEINEAGR (OVA 323-339, Th-epitope) were synthesized by automated peptide synthesis as described previously (ChronTech Pharma AB, Huddinge, Sweden). 45 Recombinant HBcAg-protein (aa 1-183) was produced in E. coli and kindly provided by Darrell Peterson (Virginia Commonwealth University, Richmond, VA). Chicken egg albumin (OVA), and Concanavalin A (ConA) were purchased from Sigma Aldrich.
IVIN device for delivery of DNA vaccine. Immunizations in this study were performed with the IVIN delivery device (unless otherwise stated) (Ahlén  et al., unpublished data) . Briefly, the IVIN is a multineedle injection device where the sharp end of the needles has been sealed and several new 0.05 mm holes in diameter have been laser cut along the needle shaft of each needle. The IVIN device used in this study consists of four needles arranged in a Y-shaped formation with all the holes facing a central point (Figure 1a) . The injection is a forced injection of 30 μl plasmid DNA controlled by the spring-loaded device. By using the IVIN device, an isolated area of the muscle tissue can be overloaded with the vaccine solution.
Immunization protocol and in vivo bioluminescence imaging. Mice were immunized intramuscularly in the tibialis cranialis muscle with 5 μg plasmid DNA coHBcAg-pVAX1 alone or in combination with 5 μg mIL-12-pORF1 in a volume of 30 μl using the in vivo injection device (IVIN) or by regular needle injection. Immediately following administration of the plasmid DNA, tibialis cranialis muscles were subsequently electroporated (EP) using the Cliniporator 2 device (IGEA, Carpi, Italy) with a 1 ms 600 V/ cm pulse followed by a 400 ms 60 V/cm pulse pattern.
Transient expression of HBcAg and luciferase in the livers of mice was achieved by hydrodynamic injection. A total volume of 1.8 ml (8% of body weight) Ringers solution containing 50 μg coHBcAg-pVAX1 and 50 μg Luc2-pVAX1 plasmid DNA was injected intravenously in the tail vein within 5 seconds. The presence of luciferase reporter gene expression was determined at 6, 24, 48, and 72 hours by bioluminescence in anaesthetized mice using the IVIS Spectrum in vivo imaging system (Caliper Life Sciences, Hopkinton, MA). To detect the presence of reporter gene expression the luciferin substrate (Caliper Life Sciences) was injected and the reporter gene expression was analyzed 10 minutes later. Images and assessment of emitted light were analyzed with the Living Image Software version 4.2. Characterization of polyfunctional T cells. 5 × 10 5 splenocytes were restimulated for 12 hours in the presence of GolgiPlug (BD Biosciences, San Jose, CA) with HBcAg CTL peptide (5 μg/ml), Th peptide (5 μg/ml), recombinant protein (0.3 μg/ml), and peptide pools (0.3 μg/ml each peptide). Staining was done using Pacific Blue rat anti-mouse CD3, PerCP rat anti-mouse CD8a, APC rat anti-mouse IL-2, FITC rat anti-mouse IFN-γ (Biolegend, San Diego, CA), PE rat anti-mouse CD107a, and PE-Cy7 rat anti-mouse TNF-α antibodies (BD Biosciences). LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Paisley, UK) was used as a dead cell marker. Permeabilization of cells was performed using the BD Cytofix/ CytopermTM Fixation/Permeabilization Kit. Cells were acquired on a LSRFortessa flow cytometer (BD Biosciences) and analyzed using FlowJo 9.6.2 software (TreeStar, Ashland, OR). From a live lymphocyte gate CD8 + T cells were identified by CD3 versus CD8 staining. These cells were analyzed for cytokine expression (IFN-γ, TNF-α, IL-2) as well as CD107a. Results were given as individual cytokines produced alone and/or in combination as percent of total CD8 + T cells. The pie charts represent the proportion of cytokine-secreting CD8 + T cells that produce one, two, three, or four cytokines/surface markers.
Detection of HBcAg-specific antibodies using ELISA. Serum from immunized C57BL/6J and HBeAg-Tg mice were tested for mouse IgG antibodies to HBcAg. In brief, plates were coated with 1 μg/ml rHBcAg in 50 mmol/l sodium carbonate buffer (pH 9.6) overnight at 4 °C. Plates were blocked by incubation with dilution buffer (phosphate-buffered saline, 2% goat serum, 1% BSA) for 1 hour at 37 °C. Mouse serum was added in serial dilutions with a starting dilution of 1:60 and then in serial dilution of either 1:2 or 1:6. Serum antibodies were detected by an alkaline phosphataseconjugated goat anti-mouse IgG (Sigma A1047) and visualized using p-nitrophenyl phosphate substrate solution. OD was read at 405 nm with a 620 nm background. The cutoff value was set to three times the OD value of a negative (nonimmunized mice) serum sample.
Detection of IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3) (Southern Biotech, Birmingham, AL) was performed in a similar manner as described above with the exception that serum antibodies were detected using subclass-specific anti-mouse horseradish peroxidase-conjugated antibodies and visualized using TMB phosphate citrate substrate solution. OD was read at 450 nm. The cutoff value was set to three times the OD value of a negative (nonimmunized mice) serum sample.
Immunohistological detection of HBcAg in mouse liver sections. Liver specimens were fixed in 10% phosphate-buffered formalin and subsequently embedded in paraffin. For histopathological evaluation, deparaffinized sections from at least two different liver lobes were stained, for each mouse, with Hematoxylin-Eosin or anti-HBcAg antibody. To retrieve antigens, liver sections were boiled in a pressure cooker. For detection of the presence of HBcAg-protein in liver tissue, a polyclonal rabbit antiHBc antibody (Dako B0586, Glostrup, Denmark) was used at a dilution of 1:3,000 in 0.01 mol/l citrate buffer complemented with 2.5% normal horse serum. Following incubation with the primary antibody, an ImmPRESS anti-rabbit Ig peroxidase detection kit was used before visualization using the DAB peroxidase substrate kit (Dako SK-4100) as a chromogen. Sections were counterstained with hematoxylin. The Hematoxylin-Eosin (H&E) staining was performed using standard techniques described in detail elsewhere.
Immuno-precipitation and western blot analysis for detection of HBcAgprotein in mouse livers. At 72 hours after generation of transient HBcAgprotein expression in mice livers by hydrodynamic injection mice were sacrificed and livers harvested for analysis of HBcAg-protein by immunoprecipitation and western blot analysis. HBcAg-expression was detected in liver homogenates. In brief, 100-mg liver were homogenized in 1 ml RIPA buffer (0.15 mol/l NaCl containing 50 mmol/l Tris, 1% Triton X-100, 1% Na-deoxycholate, and 1% sodium dodecyl sulfate (SDS)). The homogenates were immunoprecipitated with protein-A sepharose and polyclonal mouse anti-HBc overnight at 4 °C. Samples were diluted in SDS sample buffer, heated at 100 °C for 5 minutes before SDS-PAGE analysis on 4-12% Bis-Tris gel (Life Technologies) followed by ET onto nitrocellulose membranes using the iBlot (Life Technologies). HBcAg-proteins were detected using a polyclonal rabbit anti-HBc (B0586 Dako) antibody, diluted 1:1,500. Chemiluminiscence-linked Western blot kit (WesternBreeze WB7106; Life Technologies) was used for the detection of HBcAg according to the manufacturer's protocol. Chemiluminiscent signals were detected using the G:BOX Chemi XX6 gel documentation system (Syngene, Cambridge, UK).
Statistical analysis. GraphPad InStat 3, Macintosh and Microsoft Excel 2008, Macintosh was used for statistical comparison of experimental data. Kinetic measurements were compared using the AUC (Excel). Parametrical data were compared using the ANOVA and nonparametric data with Mann-Whitney U-test. Figure S1 . Loss of in vivo functional T cell responses six weeks after a single immunization.
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